2019-11-12T03:39:41-00:00 2018-12-31 KPMG LLP 1918 8th Avenue Suite 2900 Seattle WA 98101 990 2018-01-01 910653422 Benaroya Research Institute at Virginia Mason BENA 2063426500 1201 Ninth Avenue Seattle WA 98101 Michael Labosier Chief Financial Officer 2019-11-08 true Sue Robison 2069134000 204.147.223.1 2019-11-12 23:37:17 PS P 3A8BCFA172999187EBBEF58FE652F98775CE2010 3A8BCFA172999187EBBEF58FE652F98775CE2010 2018 2020-03-31 21:24:44Z Jane Buckner MD 1201 Ninth Avenue Seattle WA 98101 67982426 false X benaroyaresearch.org X 1956 WA To advance the science that will predict, prevent, reverse, and cure diseases of the immune system. 20 15 329 5 0 175948 60243416 59023034 6781431 8229643 456650 191489 347680 347680 67829177 67791846 27587861 22634522 0 25600727 26095485 0 0 18423765 18050564 71612353 66780571 -3783176 1011275 90102675 84112856 44389195 39800841 45713480 44312015 X Advancing the science that will predict, prevent, reverse, and cure diseases of the immune system such as autoimmune disease, allergy, and asthma. false false 28716066 20572090 Immune Tolerance Network Program. See Schedule O. 7982351 1239582 Immunology Program. See Schedule O. 6761683 449274 Translational Program. See Schedule O. 12330917 373576 8229643 55791017 true true false true false false false false false true true true false false false false true false false false true true false false false false false true false true true false false true false false false false false false false false false false false false true false false false false true 104 0 true 329 true true true false false false false false false false false false false false X 20 15 false false false false true true true true true false false true true true true true true true true false WA X Michael Labosier CFO 2063426505 1201 Ninth Avenue Seattle WA 98101 Jane Buckner MD Ex Officio, President 040.00 X X 389313 0 25436 Carla Greenbaum MD Director 040.00 X 231304 0 30688 Joyce Lammert MD PhD Director 001.00 050.00 X 0 648231 26064 John Corman MD Director 001.00 050.00 X 0 710194 48482 Gary Kaplan MD Director 001.00 054.00 X 0 1455167 56110 Rebecca Campbell Director 001.00 X 0 0 0 Tom Cohen Director 001.00 X 0 0 0 Carla DewBerry Director, Chair 001.00 X X 0 0 0 Frank Dvorak PhD Director, Vice-Chair 001.00 X X 0 0 0 Michael Gallatin Director 001.00 X 0 0 0 Paul Hughes Director 001.00 X 0 0 0 Nabil Istafanous Director 001.00 X 0 0 0 Margaret Morrow Director 001.00 X 0 0 0 Ben Reiber Director 001.00 X 0 0 0 Proctor Shenk Director 001.00 X 0 0 0 Diane St John Director, Secretary 001.00 X X 0 0 0 David Williams Director 001.00 004.00 X 0 0 0 Christopher Wilson MD Director 001.00 X 0 0 0 Jeffrey S Wortley Director, Treasurer 001.00 X X 0 0 0 Catherine Zimmerman Director 001.00 X 0 0 0 Homer Lane Jr Executive Director and Chief Financial Officer 040.00 X 309314 0 34906 Gerald Nepom MD PhD Program Director, ITN 024.00 X 153753 0 27192 William Kwok PhD Research Member 040.00 X 236141 0 27836 Steven Ziegler PhD Director of Academic Affairs 040.00 X 227763 0 25118 James Lord PhD Research Member 040.00 X 188133 0 22110 Margaret McCormick Chief Administrative Officer 040.00 X 185583 0 0 Lynn Rose Director Scientific Administration 040.00 X 178676 0 25105 2099980 2813592 349047 49 false true false KPMG LLP 1918 Eighth Ave Suite 2900 Seattle WA 98101 Auditing Consulting 119579 1 3000000 45278726 10744308 59023034 Commercial Studies 621500 4205104 4205104 Collaborative Research Core Service 621500 4024539 4024539 8229643 191489 191489 538260 190580 347680 347680 347680 67791846 8229643 539169 21193686 21193686 0 1440836 1440836 0 1093606 612082 481524 0 19769357 14397070 5372287 1637028 1157162 479866 2135956 1509839 626117 1459538 1031700 427838 0 18412 18412 119579 119579 0 0 2018346 1347163 671183 46839 38 46801 155551 40672 114879 1419642 701086 718556 0 2813365 2380567 432798 309419 271114 38305 0 83638 62822 20816 605267 526582 78685 0 3653748 2884897 768851 50506 30 50476 Supplies and Miscellaneous Expenses 4381748 4241266 140482 Other Purchased Services 418418 252179 166239 Patient Costs 1120222 1120215 7 Research Participants Expenses 373386 371273 2113 462478 248738 213740 66780571 55791017 10989554 0 6125815 5711406 363312 576745 13584865 11995906 1647502 1591784 400177 509432 73401017 48486896 27235510 24914121 12181585 12066383 27320900 25745020 1243009 1002059 90102675 84112856 11146141 9535580 6511564 4548771 26731490 25716490 44389195 39800841 X 18078247 17232381 13575861 12465089 14059372 14614545 45713480 44312015 90102675 84112856 1011275 -2412740 X false true X true true true X Virginia Mason Medical Center Seattle WA 54174085 59709893 71346495 60243416 59023034 304496923 54174085 59709893 71346495 60243416 59023034 304496923 29172644 275324279 707157 430555 933027 994910 729749 3795398 6639555 7021290 8553010 6781431 8229643 37224929 345517250 0.79680 0.79860 X 0.00000 0.00000 Part II Section B Line 10 2018 Other Income of 8,229,643 is comprised of 4,205,104 of Clinical Research Program revenue, 3,447,597 of Collaborative Research Agreement projects, 545,781 of External Core Income, and 31,161 of miscellaneous income. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X 180464 113574 294038 66780571 1685581835 66780571 1685875873 1000000 1000000 250000 250000 1000000 1000000 1000000 1000000 4000000 6000000 154766 275782 284247 294038 1008833 250000 250000 250000 250000 1000000 1500000 108173 163134 175480 180464 627251 false false false false false false false false false false false II-A A Benaroya Research Institute at Virginia Mason, EIN 91-0653422, 1201 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0. II-A A continued Virginia Mason Health System, EIN 91-1351110, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0 II-A A continued Virginia Mason Institute, EIN 26-3763656, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures, 0 Excess Lobbying Expenditures. II-A A continued Virginia Mason Medical Center, EIN 91-0565539, 1100 Ninth Avenue, Seattle, WA 98101. Electing member. Grassroots Lobbying Expenditures 133, 835 Direct Lobbying Expenditures 53,574. Excess Lobbying Expenditures 0. Tax year ending December 31, 1998 was the first year in which Virginia Mason Medical Center made the election under Section 501h. The election was not revoked before the start of the tax year ending December 31, 2018. II-A A continued Yakima Valley Memorial Hospital Association, EIN 91-0567263, 2811 Tieton Drive, Yakima, WA 98902. Non-electing member. 46,629 Grassroots Lobbying Expenditures 60,000 Direct Lobbying Expenditures. Excess Lobbying Expenditures 0. false false true true 756906 756906 49563103 28751108 20811995 215595 197799 17796 22340094 19537989 2802105 525319 525319 24914121 Financial derivatives and other financial products Closely-held equity interests Interest in Net Assets of Virginia Mason Health System 25745020 F 25745020 Federal income taxes 65379106 -2412740 -2412740 67791846 67791846 66780571 66780571 66780571 true Europe Including Iceland and Greenland Conferences Medical Research 40987 East Asia and the Pacific Conferences Medical Research 1492 North America Conferences Medical Research 940 Europe Including Iceland and Greenland Grant Medical Research 1091093 East Asia and the Pacific Grant Medical Research 324472 North America Grant Medical Research 25271 1484255 1484255 Europe Including Iceland and Greenland Medical Research 398678 Wire Transfer Europe Including Iceland and Greenland Medical Research 376854 Wire Transfer Europe Including Iceland and Greenland Medical Research 166166 Wire Transfer Europe Including Iceland and Greenland Medical Research 149395 Wire Transfer East Asia and the Pacific Medical Research 138406 Wire Transfer East Asia and the Pacific Medical Research 88854 Wire Transfer East Asia and the Pacific Medical Research 67344 Wire Transfer East Asia and the Pacific Medical Research 29868 Wire Transfer North America Medical Research 12707 Wire Transfer. North America Medical Research 12564 Wire Transfer 10 false false false false false false Part I Line 2 Sub-recipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing federal grants. The Sub-recipient Monitoring Policy provides assurance that sub-recipients comply with federal grant regulations. This policy sets the criteria to establish eligibility of sub-recipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of sub-recipient internal controls and a standardized risk assessment is presented to management on each sub-recipient. A Management Letter is issued to each sub-recipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring sub-recipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. Part I Line 3f The expenditures were actual expenses incurred in the region based on individual expense reports and tracking of expenditures by grant or department on the accrual basis of accounting. Part II Line 1 The expenditures were expenses incurred in the region based on award goals on the accrual basis of accounting. true Ann&Robert H Lurie Children's Hospital of Chicago 225 East Chicago Ave No 205 Chicago IL 606112991 362170833 501c3 23919 Medical Research Arkansas Children's Hospital Research Institute One Childrens Way Little Rock AR 722023591 710694931 501c3 56884 Medical Research Asthma Inc 9725 3rd Ave NE Seattle WA 98115 237219813 501c3 27685 Medical Research Regents of the University of Colorado Barbara Davis Center Aurora CO 80045 846000555 501c3 19546 Medical Research Baylor Research Institute 3301 Live Oak Dallas TX 75204 751921898 501c3 9468 Medical Research Boston University 25 Buick Street Suite 200 Boston MA 02215 042103547 501c3 22524 Medical Research Brigham And Women's Hospital Bank of America NA Boston MA 022413887 042312909 501c3 16723 Medical Research Case Western Reserve University 10900 Euclid Avenue Cleveland OH 441067037 341018992 501c3 16496 Medical Research Children's Hosp of Philadelphia PO Box 8550 Philadelphia PA 191781457 231352166 501c3 79823 Medical Research Children's Mercy Hospital 2401 Gillham Road Kansas City MO 64101 440605373 501c3 62426 Medical Research The Cleveland Clinic Foundation 9500 Euclid Avenue JJN5-001 Cleveland OH 44195 340714585 501c3 46478 Medical Research Columbia University Trustees of PO Box 29789 New York NY 100879789 135598093 501c3 89803 Medical Research Dana-Farber Cancer Institute Inc 450 Brookline Ave 431C Boston MA 02215 042263040 501c3 288099 Medical Research Denver Nephrologists PC 130 Rampart Way Suite 300B Denver CO 80230 840591433 17583 Medical Research Dermatology Research Assoc Inc 8930 S Sepulveda Blvd Ste 114 Los Angeles CA 90045 273947370 14114 Medical Research Duke University PO Box 602651 Charlotte NC 282602651 560532129 501c3 392135 Medical Research Emory University PO Box 935084 Atlanta GA 311935084 580566256 501c3 125560 Medical Research Feinstein Institute for Medical Research 350 Community Drive Manhasset NY 11030 112673595 501c3 9819 Medical Research Fred Hutchinson Cancer Research Center PO Box 19024 Seattle WA 98109 237156071 501c3 93900 Medical Research Georgetown University 2121 Wisconsin Ave NW Washington DC 20007 530196603 501c3 19774 Medical Research Icahn School of Medicine at Mount Sinai One Gustave L Levy Place Box 3500 New York NY 100296574 136171197 501c3 531892 Medical Research Indiana University Dept 78867 Detroit MI 482780867 356001673 501c3 194353 Medical Research Johns Hopkins University Central Lockbox co B of A Chicago IL 60693 520595110 501c3 437963 Medical Research Jonathan Corren MD Inc 10780 Santa Monica Blvd 280 Los Angeles CA 90025 462346264 69580 Medical Research Joslin Diabetes Center One Joslin Place Boston MA 022155306 042203836 501c3 166926 Medical Research Massachusetts General Hospital PO Box 3829 Boston MA 022413829 042697983 501c3 5825904 Medical Research Medical University of South Carolina 19 Hagood Avenue Ste 604 Charleston SC 29425 576000722 South Carolina 26593 Medical Research National Jewish Health 1400 Jackson Street M213 Denver CO 80206 742044647 501c3 11630 Medical Research New York University-School of Medicine PO Box 415026 Boston MA 022415026 135562308 501c3 5140 Medical Research Northwestern University 633 Clark Room G547 Evanston IL 60208 362167817 501c3 143741 Medical Research Ohio State University Office of Sponsored Programs Columbus OH 43210 316025986 501c3 13663 Medical Research Oklahoma Medical Research Foundation 825 NE 13th Street Oklahoma City OK 73104 730580274 501c3 49310 Medical Research Polyclinic Madison Center 904 7th Ave Seattle WA 98104 910369070 501c3 39076 Medical Research Research Foundation State University of New York PO Box 9 Albany NY 122010009 141368361 501c3 33951 Medical Research Rockefeller University 1230 York Ave New York NY 100656307 131624158 501c3 58559 Medical Research Rutgers the State University of New Jersey Office of Research and Sponsored Pr New Brunswick NJ 089018559 226001086 501c3 351310 Medical Research Sanford Research 2301 E 60th St N Sioux Falls SD 57104 460450378 501c3 153414 Medical Research Seattle Childrens Hospital PO Box 24728 Seattle WA 981240728 910564748 501c3 471632 Medical Research Stanford University PO Box 44253 San Francisco CA 941444253 941156365 501c3 394510 Medical Research State University of Iowa 118 S Clinton St - SCST Iowa City IA 52242 426004813 Iowa 91733 Medical Research St Jude Children's Research Hospital Inc PO Box 1000 Dept 949 Memphis TN 381480949 620646012 501c3 280794 Medical Research Tulane University 1430 Tulane Ave Dermatology 8036 New Orleans LA 70112 720423889 501c3 15653 Medical Research Unitversity of Washington Grants 4333 Brooklyn Ave NE Seattle WA 98195 916001537 Washington 666763 Medical Research Univ of Minnesota Regents NW 5957 Minneapollis MN 554855957 416007513 Minnesota 103635 Medical Research Univ of Texas SW Med Ctr Grants Management Dallas TX 752841753 756002868 Texas 85417 Medical Research University of Colorado-Denver PO Box 910238 Denver CO 802910238 846000555 501c3 349778 Medical Research University of Pennsylvania PO Box 785541 Philadelphia PA 171785541 231352685 501c3 148795 Medical Research University of Florida Board of Trustees PO Box 113001 Gainesville FL 32611 596002052 501c3 22020 Medical Research University of Texas Southwestern Medical Center 5323 Harry Hines Boulevard Dallas TX 75390 756002868 501c3 7977 Medical Research University of Nebraska Medical Center 985045 Nebraska Medical Center Omaha NE 681985045 470049123 501c3 33458 Medical Research University of Michigan Box 223131 Pittsburgh PA 152512131 386006309 501c3 87206 Medical Research University of North Carolina at Chapel Hill PO Box 402420 Atlanta GA 303842240 566001393 501c3 245134 Medical Research University of Utah Grants and Contract Accounting Salt Lake City UT 84132 876000525 501c3 14726 Medical Research University of Massachusetts Worcester 55 Lake Avenue North Worchester MA 016550002 043167352 501c3 54605 Medical Research University of Chicago 5841 S Maryland Ave Chicago IL 60637 362177139 501c3 28577 Medical Research University of California San Francisco Controllers Office San Francisco CA 941430897 946036493 501c3 7721453 Medical Research University of Pittsburgh Research Cost Accounting Pittsburgh PA 152517220 250965591 501c3 326822 Medical Research University of Michigan Regents of the Box 223131 Pittsburgh PA 152512131 386006309 501c3 16084 Medical Research University of Miami 1320 S Dixie Highway Coral Gables FL 331462926 590624458 501c3 12968 Medical Research University of California Los Angeles 11000 Kinross Ave Ste 211 Los Angeles CA 90095 956006143 501c3 42724 Medical Research University of Wisconsin Board of Regents 600 Highland Ave Madison WI 53792 Madison WI 53792 396006492 501c3 29550 Medical Research University of Texas Health Science Center Houston 7000 Fannin St Houston TX 770305400 741761309 Texas 39699 Medical Research Vanderbilt University Department of Finance Dallas TX 753121236 620476822 501c3 170809 Medical Research Vital Prospects Clinical Research Institute PC 7307 S Yale Ave Suite 200 Tulsa OK 74136 261814411 13724 Medical Research Wake Forest University Health Sciences Medical Center Boulevard WinstonSalem NC 27157 223849199 501c3 13504 Medical Research Yale University Grant and Contract Financial Admini New Haven CT 065081873 080648973 501c3 201707 Medical Research 62 4 Part I Line 2 Sub-recipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing federal grants. The Sub-recipient Monitoring Policy provides assurance that sub-recipients comply with federal grant regulations. This policy sets the criteria to establish eligibility of sub-recipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of sub-recipient internal controls and a standardized risk assessment is presented to management on each sub-recipient. A Management Letter is issued to each sub-recipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring sub-recipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. X X true true false false false false false false false false false Jane Buckner MD Ex Officio, President 342329 46984 24500 936 414749 Carla Greenbaum MD Director 231304 24500 6188 261992 Joyce Lammert MD PhD Director 481542 73657 93032 14350 11714 674295 John Corman MD Director 600505 90775 18914 26467 22015 758676 Gary Kaplan MD Director 1150154 283313 21700 14350 41760 1511277 Homer Lane Jr Executive Director and Chief Financial Officer 269715 39599 24500 10406 344220 Gerald Nepom MD PhD Program Director, ITN 153753 24000 3192 180945 William Kwok PhD Research Member 236141 24500 3336 263977 Steven Ziegler PhD Director of Academic Affairs 227763 17330 7788 252881 James Lord PhD Research Member 188133 17634 4476 210243 Margaret McCormick Chief Administrative Officer 185583 185583 Lynn Rose Director Scientific Administration 178676 18389 6716 203781 Part I Line 1a Social club dues are provided to two members of the senior leadership team who use the club memberships for business purposes. These payments are treated as non-taxable. Part I Line 3 Benaroya Research Institute at Virginia Mason BRI delegates to Virginia Mason Health Systems its parent and sole member Board Compensation and Benefits Committee, a committee composed of independent Health System Board members to whom the BRI Board has delegated the authority to approve all compensation and benefits for the executive leaders of BRI. To ensure that such benefit plans are market competitive and reasonable, the Committee receives support and advice, including appropriate market comparability data from an independent compensation consultant with expertise in the health care industry and access to relevant market data. See Schedule O for additional disclosure. Part I Line 4b The Virginia Mason Medical Center has a Supplemental Executive Retirement Plan SERP in which certain BRI Executives participate. The SERP is a 457 f nonqualified deferred compensation plan pursuant to which plan benefits are subject to a substantial risk of forfeiture, entered into in connection with certain senior executives joining the Medical Center. The plan was approved by the Boards Compensation and Benefits Committee, a committee composed of independent board members to whom the Board delegates the authority to approve compensation and benefits to the Medical Centers most senior executives. The Committee receives advice from an independent compensation consultant to ensure that compensation and benefits, including the SERP, are market competitive and reasonable. Supplemental Executive Retirement Plans such as this are customary for senior executives in the health care industry. A WA Econ Devel Fin Auth-2012 Series B 911493002 000000000 2012-06-01 10390000 See Part VI false true false B WA Econ Devel Fin Auth-Series 2016 911493002 000000000 2016-06-01 18631490 See Part VI false true false A 1995000 10390348 2550348 7840000 2013 true false true true B 1310000 18631490 18631490 true false true true A false true false true true 0.02030 0.02030 false false true B false true false true true 0.02030 0.02030 false false true A false true false false false false true B false true false false false false true A true B true Part I Line A Column F. Purposes to currently refund WEDFA Series 2006C bonds issued 11/15/2006, and to fund research facility improvements. Part I Line B Column F. Purposes to currently refund WEDFA Series 2012A taxable bonds issued 06/01/2012. No tax-exempt private activity bonds are being refunded. Part I Line A, B Difference between Part I, column e and Part II, Line 3 is investment earnings. Line B Difference between Part I, column e and Part II, Line 3 is investment earnings. Form 990, Part III, Line 1 Benaroya Research Institute at Virginia Mason BRI is a world-renowned, non-profit research institute committed to advancing the science that will predict, prevent, reverse and cure diseases of the immune system. BRI researchers uniquely study the immune system in both health and disease, with the ultimate goal of achieving a healthy immune system for each individual. Diseases we study include type 1 diabetes, rheumatoid arthritis, lupus, multiple sclerosis, Crohns and colitis as well as allergies and cancer. BRI accelerates discovery through laboratory breakthroughs in immunology that can be translated to clinical therapies. BRI is affiliated with the Virginia Mason Health System, which provides governance oversight and the Virginia Mason Foundation provides development support. In 2018, BRI scientists led four international centers for autoimmune disease research and collaborated with colleagues all over the world. These researchers generated 76 scientific publications that were published in prestigious research journals, delivered 82 presentations at domestic and international research conferences and received many grants. Nearly half of BRIs research faculty also serve as affiliate professors at the University of Washington and mentor postdoctoral fellows, graduate students and summer interns. Their leadership, expertise, collaboration, dedication and curiosity drive our pioneering discoveries. BRI is led by President Jane H. Buckner, MD, and Executive Director/COO Margaret McCormick, PhD. About the Diseases BRI Studies One in 15 Americans suffers from an autoimmune disease, and 25 of those have more than one. Even more Americans, about one in five, suffer from an allergy, which is an immune system related disease. A recent BRI discovery linked a protein found in asthma and other allergic disease to also be a key player in metastatic breast cancer. This illustrates how immune system diseases are connected and how research in one disease can have implications across many other diseases. Form 990, Part III, Line 4 One unique quality of BRI is the close integration of three types of medical research - laboratory research, translational research and clinical research - to improve lives. Our scientists collaborate to explore the basic science issues as well as clinical applications, which is the best way to design studies with the highest potential for success. For BRI, discovery starts in the laboratory but is driven by patient issues addressed in the clinic. 2018 advancements of the Immune Tolerance Network and in BRIs immunology, translational and clinical research, among other areas are highlighted below. Form 990, Part III, Line 4a Funding for the Immune Tolerance Network ITN was awarded to BRIs Dr. Jerry Nepom in 2014 from the National Institute of Allergy and Infectious Disease NIAID of the National Institutes of Health NIH. The 7-year award, totaling 27 million annually supports the ITN, a research consortium established in 1999 with a primary focus on the development of new tolerogenic approaches for the treatment and prevention of disease in three clinical areas asthma and allergic diseases autoimmune diseases and immune-mediated rejection of transplanted solid organs, tissues and cells. As the Prime recipient of this grant, BRI is responsible for the management of the overall grant from NIAID including oversight of all aspects of the Networks infrastructure. The major activities in 2018 were diverse, but continued to center on preserving the ITNs cohesive project focused environment and its framework which has proven so successful in the management of a large cooperative agreement grant. Key outcomes in 2018 include the following 1 Cross Network Integration A top priority in this reporting period was to continue the successful ITN infrastructure which is spread across three main operational sites. This required careful planning and collaboration as the ITNs major centers of operations are geographically diverse, located in Seattle, San Francisco and Bethesda. Few changes were made to the existing network integration as the current model continues to successfully support the overall ITN program. Establishing new relationships and vital connections within the research community continued to be an ITN goal. Form 990, Part III, Line 4a continued Immunology Research Program advances include 1 Personalized Treatments for Peanut Allergy - BRI received a grant to accelerate discovery of treatments for peanut allergy through a collaboration involving three BRI labs, Virginia Mason physicians and sponsors of two clinical trials. This two-pronged study first researches peanut allergy patients immune responses and classifies them into subgroups. Secondly, researchers evaluate treatment options being used in a pair of clinical trials to determine how specific treatments can be matched to specific patients to teach their immune systems to tolerate peanut protein. 2 Uncovering a New Strategy for Stopping Breast Cancer - Scientists at BRI made a discovery that opens the door to a potentially game-changing way to stop breast cancer tumors from growing and spreading. The researchers pinpointed how a protein called thymic stromal lymphopoietin TSLP helps breast cancer tumors survive and grow. Even more significant, the researchers showed that blocking TSLP in model systems can significantly inhibit the growth of breast tumors and halt metastasis to the lungs. The study was published in Nature Immunology. 3 Discovering how Lupus is Triggered - Lupus is one of the most difficult autoimmune diseases to diagnose and treat. Clinicians and researchers at Virginia Mason and BRI made a new discovery regarding how lupus is triggered, and began to explore how the newly discovered mechanism works and how to affect it. The mechanism prevents the immune system from reacting to the debris that leaks from cells as they die. A new grant will allow the research team to understand how this mechanism works in a particular type of immune cell, the plasmacytoid dentdritic cell, which can serve as a master regulator of immune responses and has been heavily implicated as a major contributor to lupus and other autoimmune diseases. Form 990, Part III, Line 4b Translational research is a scientific approach that allows research observations made in the basic research lab to be quickly tested in the clinic with patients, and results brought back to the lab again in an expedient and systematic way. This research is translating new methods that improve our ability to predict disease risk, prevent onset of disease, decrease disease progression and make treatments safer and better. The research emphasis of the BRI Translational Research Program is in the areas of autoimmune and immune-mediated diseases. The BRI biorepository, or biobank, is a collection of blood, serum and tissue samples, as well as medical histories, from volunteers with and without autoimmune and immune system diseases. BRI scientists and physician collaborators work together to study the blood serum samples along with medical and demographic data collected from people with autoimmune and immune-mediated diseases. These include multiple sclerosis, type 1 diabetes, lupus, rheumatoid arthritis, inflammatory bowel disease, allergy and asthma. BRIs biorepository samples date back to 2000 and include multiple disease categories and a biorepository of healthy people for comparison purposes. Advancements in 2018 included the following 1 Autoimmune Disease Research in the Down Syndrome Population - BRI scientists were awarded a one-year grant to build a Down Syndrome DS biorepository to research the connection between autoimmune disease and DS. The grant will help fund a dedicated biorepository for people with DS with and without autoimmune diseases, who are willing to donate a blood sample and provide health information for scientific research. The DS population has been underrepresented in medical research, especially considering nearly 50 percent of this population have an autoimmune disease AID, among other immune system diseases. Form 990, Part III, Line 4c Type 1 diabetes is a focal point of research at BRI. As an international leader in type 1 diabetes research, starting with identification of a genetic marker over 30 years ago, BRI is dedicated to finding biomarkers and therapies that predict, prevent, reverse and ultimately eliminate this disease. Advancement in 2018 included the following 1 Discovery of a new type 1 diabetes attacker cell A team of researchers at BRI discovered that patients with type 1 diabetes have a unique set of T cells that have grown and multiplied, increasing the numbers of bad cells that can attack the pancreas. This information can be used to decode the bad cells and find out what makes them tick. These unique T cells are rare in healthy individuals, but exist in significantly higher numbers in patients with type 1 diabetes. These T cells are part of an army that attacks the insulin-producing cells in the pancreas, destroying them so they cant make insulin anymore. The team is now working to understand when these unique T cells appear. If they can be found before a patient develops symptoms of type 1 diabetes, the presence of these cells could be used to monitor disease progression or serve as a target for treatments to preserve the bodys ability to produce insulin. 2 Waking Up Beta Cells Study - BRI is leading the first study involving adults who have lived with T1D over the long-term, to see if a drug could kick start sleeping beta cells so they make full-fledged insulin. This study is only available at BRI and at another site in Idaho. BRI leads the Type 1 Diabetes TrialNet, an international network of leading academic institutions, physicians, scientists and healthcare teams dedicated to the prevention of type 1 diabetes. TrialNet offers risk screening for relatives of people with type 1 diabetes and innovative clinical studies to preserve insulin production. 3 The TrialNet Pathway to Prevention study - Now anyone who tests positive for two or more autoantibodies can be classified as having stage one T1D. This helps doctors know when patients are in the diseases pre-symptom stages, so they can plan treatment. Its how high blood pressure can predict heart attack and stroke. Today, we can treat high blood pressure long before someone experiences heart symptoms or complications. The same is becoming true for T1D. We can match people in stage one with clinical trials of therapies that try to prevent the disease or slow it down. Home to the JDRF Core for Clinical Assay Validation CAV, BRI plays an important role in identifying type 1 diabetes biomarkers and in helping outside researchers get the most accurate test results. The CAV is pinpointing key biomarkers, such as those indicating which patients will keep making insulin for years and which patients wont. The CAV also helps maintain quality control for a worldwide network of research labs by asking them to perform specific tests and reviewing their results. Form 990, Part III, Line 4d 1 The Clinical Research Program at BRI oversees all clinical research at Virginia Mason Medical Center which uniquely combines the expertise of a world-renowned medical research institute with the remarkable care of a healthcare quality leader. The BRI Clinical Research Program supports Virginia Mason clinical investigators in studies across a wide variety of autoimmune and immune-mediated diseases and conditions, as well as a broad range of other diseases such as cancer and cardiac disease. Each year the Clinical Research Program staff annually enrolls approximately 1500 study participants into Virginia Mason trials. This program involves approximately 170 research investigators, oversees more than 500 active studies with more than 275 studies currently open to enrollment. 2 Evaluating Immune Responses to Gluten BRI scientists are studying the use of short-term gluten challenge in celiac disease as a model to assess antigen-specific immune responses in humans. In people with celiac disease, T cells in the intestine recognizing a protein found in gluten gliadin deamidated peptide are activated by antigen presenting cells after oral ingestion of gluten. The activation of these cells results in a series of cascading immune responses. To better understand the immune cells involved when the growth of cancer cells goes unchecked, immunologists at BRI, along with physicians at Virginia Mason, are involved in a research collaboration in which blood samples are taken from patients before and after receiving immune checkpoint inhibitors. A comparison of these blood samples enable the characterization of tumor-attacking immune cells and the search for associated biomarkers for cancer and response to therapy. 3 Testing a New MS Therapy - a new research study at BRI and Virginia Mason sought to find out if an experimental oral drug, similar to a currently available MS medication, would be just as effective as the current one, but with fewer gastrointestinal side effects. In the initial study, half the research participants took this experimental drug and half took the current drug. Participants who finished the five-week study could then enroll in a two-year study of the experimental drug, currently under way. Form 990, Part VI, Section A, Line 1a The governing body delegates to an Executive Committee comprised of four officers of the Board and the Chairs of each standing Board Committee, the authority of the Board of Directors in the management of the corporation as may be deemed by the Executive Committee to be appropriate, to be exercised in time periods between regularly scheduled meetings of the Board of Directors provided that the Executive Committee has the authority to act only in time sensitive or emergency situations. The Director and the Executive Director of the corporation serve as ex officio members of the Executive Committee without voting rights. The Executive Committee does not have the authority to amend, alter or repeal the bylaws elect, appoint or remove any member of such Executive Committee or any director or officer of the corporation amend the articles of incorporation adopt a plan of merger or adopt a plan of consolidation with another corporation authorize the sale, lease or exchange of all or substantially all the property and assets of the corporation not in the ordinary course of business authorize the voluntary dissolution of the corporation or revoke proceedings therefore adopt a plan for the distribution of the assets of the corporation or amend, alter or repeal any resolution of the Board which by its terms provides that it shall not be amended, altered or repealed by such Executive Committee. The Executive Committee also serves as the planning committee for the Board of Directors and oversees any compliance issues raised by the Board of Directors. Form 990, Part VI, Section A, Line 6, 7 Virginia Mason Health System VMHS is the sole corporate member of Benaroya Research Institute at Virginia Mason BRI. VMHS as the sole voting member has the following approval rights a election or appointment of Directors and Officers of the Board of Directors b removal of Directors and Officers of the Board of Directors including any executive officer of the corporation c approval of all long-range and short-range plans proposed by the Board of Directors d approval of the annual capital and operating budgets proposed by the Board of Directors e approval of the borrowing of funds where the amount borrowed is in excess of Five Hundred Thousand Dollars 500,000 f approval of the sale, lease, exchange, mortgage, pledge or disposal of all or substantially all of the property and assets g approval of all amendments to or repeal of the Agreement Association or the Bylaws of the corporation h all other rights and powers as specified in the Washington Nonprofit Corporation Act. Form 990, Part VI, Section B, Line 11b The Virginia Mason Health System Audit and Compliance Committee ACC, a committee composed of independent community members has been delegated responsibility for oversight of the annual Form 990 preparation process including a selection, engagement, and review of the performance of the independent tax preparer b review of the annual draft Form 990 tax return, and c recommendation of the final Form 990 tax return for review to the BRI Board of Directors. Annually, at the September meeting, management and the tax preparer provides the ACC with an initial draft of the Form 990 and present an overview of the Form 990 preparation process. The final draft Form 990 is reviewed and approved by the ACC in November followed by a Board review of the final Form 990 prior to filing. The final Form 990 tax return is provided to each member of the Board of Directors via electronic delivery. Form 990, Part VI, Section B, Line 12c The Virginia Mason Health System Governance Committee has been delegated accountability for oversight of the process for disclosure, evaluation and management of conflict of interest involving any member of the Benaroya Research Institute at Virginia Mason BRI Board of Directors, executive leadership or key employees Covered Person. Pursuant to the Conflict of Interest Policy, an annual conflict of interest questionnaire is distributed to all Covered Persons. In addition, a Covered Person has an on-going duty to disclose the existence of a conflict of interest at any time an actual or potential conflict arises. Each Covered Person is required upon appointment and annually thereafter to attest to a statement that affirms that such person has a received a copy of the Conflict of Interest Policy b has read and understands the Policy c has agreed to comply with the Policy and d understands that BRI is a charitable organization and that in order to maintain its federal tax exemption must engage in activities that accomplish its tax-exempt purposes. Written disclosures are reviewed by the Governance Committee to determine if an actual or potential conflict of interest exists and if so, how it should be managed. The Covered Person is informed in writing regarding the determination the Conflict of Interest Management Plan. No Covered Person with an actual or potential conflict of interest shall engage in an activity on BRIs behalf related to the disclosed actual or potential Conflict of Interest unless such activity is permitted by the Conflict of Interest Management Plan or until the Covered Person has undertaken all steps set forth in the Management Plan to manage, reduce or eliminate the conflict. All Covered Persons have a duty to disclose the existence of any actual or potential conflict of interest with respect to meeting agenda items. The Conflict of Interest Policy requires that copies of the Conflict of Interest Questionnaire be completed annually by each Covered Person and any Conflict of Interest Management Plan be maintained. Form 990, Part VI, Section B, Line 15 The VMHS Compensation and Benefits Board Committee, a committee composed solely of independent directors none of whom have a conflict of interest, is accountable for setting reasonable total compensation packages for each executive, officer and key employee Executive consistent with BRIs compensation philosophy and principles. The Committee approves annual goals and performance criteria which are used in determining merit increases and variable compensation opportunities. The Committee assesses performance against these goals. The Committee selects and engages a qualified independent compensation consultant to review and analyze the total compensation and benefits packages of the Executives. The Committee as part of its analysis obtains from the compensation consultant appropriate comparability data including total compensation paid by similarly situated organizations for positions that are functionally comparable to each of the Executives. The Committee will consider the significant terms of the agreement with each Executive including the total compensation to be paid and the employees duties and responsibilities. Consistent with the compensation philosophy and principles, the Committee approves total compensation packages for each of the Executives based on information presented to the Committee, reasonableness and the best interest of BRI. The Committees decisions regarding compensation for each Executive are documented in written resolutions and minutes of the Committee. The Committee promptly reports its actions to the VMHS board which reports are reflected in the Boards minutes. The individual positions who were reviewed in 2018 were Jane Buckner, BRI President and Director, Carla Greenbaum, BRI Director, and Homer Lane, Executive Director and Chief Financial Officer. Form 990, Part VI, Section C, Line 19 The organizations Articles, Bylaws, Conflict of Interest Policy and financial statements are made available upon request. Virginia Mason Health System 1100 Ninth Avenue Seattle WA 98101 911351110 Fundraising WA Sec 501c3 7 N/A true Virginia Mason Medical Center 1100 Ninth Avenue Seattle WA 98101 910565539 Health Care WA Sec 501c3 3 VMHS false Virginia Mason Institute 1100 Ninth Avenue Seattle WA 98101 263763656 Education WA Sec 501c3 9 VMMC false Yakima Valley Memorial Hospital Association 2811 Tieton Drive Yakima WA 98902 910567263 Health Care WA Sec 501c3 3 VMHS false Children's Village 3801 Kern Rd Yakima WA 98902 352654720 Supporting Organization WA Sec 501c3 12 N/A false false false true false false false false false false true true false false true false true true false false Benaroya Research Institute at Virginia Mason 1201 Ninth Avenue Seattle WA 98101 910653422 0 0 0 66780571 66780571 39612 9903 0 0 0 Virginia Mason Health System 1100 Ninth Avenue Seattle WA 98101 911351110 0 0 0 24630107 24630107 14610 3653 0 0 0 Virginia Mason Medical Center 1100 Ninth Avenue Seattle WA 98101 910566539 X 133835 53574 187409 1108735210 1108922619 657772 164443 0 0 0 Virginia Mason Institute 1100 Ninth Avenue Seattle WA 98101 263763856 0 0 0 6889011 6889011 4086 1022 0 0 0 Yakima Vallley Memorial Hospital Association 2811 Tieton Drive Yakima WA 98902 910567263 46629 60000 106629 478546936 478653565 283920 70980 0 0 0